Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis - an open randomized comparative study
Keywords:
Tacrolimus, FK506, clobetasone butyrate, atopic dermatitis, efficacy, safetyAbstract
Background Atopic dermatitis, a chronic recurring inflammatory skin disease, often requires long-term use of topical corticosteroids that may cause serious adverse effects. Therefore, steroid sparing topical agent is needed. Objective In this open, randomized and comparative study, the efficacy and safety of 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream and their combination were evaluated in patients with AD. Patients and methods 45 patients with moderate to severe AD involving with moderate to severe AD involving ≤50% of the total body surface area (BSA) were randomly assigned to three groups. 15 patients in each group received 0.03% tacrolimus ointment twice daily (arm A) or 0.05% clobetasone butyrate cream twice daily (arm B) or 0.05% clobetasone butyrate cream in the morning and 0.03% tacrolimus ointment in evening (arm C). The treatment duration was 4 weeks and was followed-up for 6 weeks. The modified eczema area and severity index (mEASI) and the extent of the affected BSA were assessed and evaluated. Results All treatment groups showed significant improvement throughout the treatment period. At the end of 4 weeks treatment, a median improvement of ≥75% in mEASI was observed in 53.3%, 73.3% and 93.3% of patients in arms A, B and C, respectively (endpoint analysis 1) and at the end of follow-up this improvement remained at the rate of 87.5%, 63.6% and 85.7% respectively (endpoint analysis 2). Only 13.3% patients who received 0.03% tacrolimus ointment experienced excellent improvement and clearance by the end of the treatment compared with 66.7% patients who received 0.05% clobetasone butyrate and 93.3% patients who received combination regimens. Skin burning was common in the 0.03% tacrolimus treatment group than in the 0.05% clobetasone butyrate group (7/15 vs. 1/15, p=0.010) and in the combination regimen group (7/15 vs.2/15, P=0.042). Conclusion The overall therapeutic effectiveness and safety were in favor of combination regimens.References
Carr RD, Belker RW. Adrenocortical suppression with small doses of topical corticosteroids. Acta Derm Venereol 1968; 49: 508.
Bekersky I, Lilja H, Lawrence I. Tacrolimus pharmacology and nonclinical studies: from FK506 to protopic. Semin Cutan Med Surg 2001; 20(4): 226-32.
Kapp A, Allen B, Reitamo S. Atopic dermatitis management with tacrolimus ointment (Protopic®). J Dermatolog Treat 2003; 14: 5-16.
Freeman AK, Ljnowski GJ, Brady C, Lind L, Vanveldhuisen P, Singer G, Lebwohl M. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003; 48: 564-8.
Fleischer AB Jr, Ling M, Eichenfield L, Jaracz E, Rico MJ, Maher RM. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infection. J Am Acad Dermatol 2002; 47: 562-70.
Lassus A. Clobetasone butyrate and hydrocortisone butyrate in the treatment of eczema: a double-blind comparison. Curr Med Res Opin 1979; 6: 165.
Munro DD, Wilson Lyn. Clobetasone butyrate, a new topical corticosteroid: clinical activity and effects on pituitary-adrenal axis function and model of epidermal atrophy. Br Med J. 1975; 3: 626-628.
Boner AL, Richelli C, De Stefano G, Valletta EA, Ferrari S, Mengoni M. Hypothalamic-pituitary-adrenal function in children with atopic dermatitis treated with clobetasone butyrate and its clinical evaluation. Int J Clin Pharm ther Tox 1985; 23: 118-120.
Morley N, Fry L, Walker S. Clinical evaluation of clobetasone butyrate in the treatment of children with atopic eczema and its effect on plasma cortisol levels. Curr Med Res Opin 1976; 4(3): 223-228.
Hanifin JM, Rajka G. Diagnostic feature of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; 92: 44-47.
Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol (Stockh) 1989; 144: 13-14.
Hanifin JM, Thurston M, Ornoto M, Cherill R, Tofte SJ, Graber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001; 10: 11-18.
Coleman R. et al. Genetic studies of atopy and atopic dermatitis. Br. J. Dermatol. 1979; 136: 1.
Reitamo S, Van Leent E JM, Vincent HO, Harper J et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002; 109: 539-546.
Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM, The tacrolimus ointment study group. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: S58-64.
Alaiti S, Kang S, FiedlerVC. ointment(FK506) for atopic dermatitis: a phase 1 study in adult and children. J Am Acad Dermatol 1998; 38: 69-76
Rico MJ, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacological effects. Allergy Asthma Proc. 2002; 23: 191-7.
Pustisek N, Lipozencic J, Ljubojevic S. Tacrolimus ointment: a new therapy for atopic dermatitis - review of the literature. Acta Dermatovenerol Croat. 2002; 10: 25-32.
